Wherrett Diane K, Chiang Jane L, Delamater Alan M, DiMeglio Linda A, Gitelman Stephen E, Gottlieb Peter A, Herold Kevan C, Lovell Daniel J, Orchard Trevor J, Ryan Christopher M, Schatz Desmond A, Wendler David S, Greenbaum Carla J
Department of Pediatrics, University of Toronto, Toronto, Canada.
American Diabetes Association, Alexandria, VA.
Diabetes Care. 2015 Oct;38(10):1975-85. doi: 10.2337/dc15-1429.
Emerging data suggest that type 1 diabetes is a more aggressive disease in children than in adults, with important differences in pathophysiology and clinical course. Therefore, the efficacy of disease-modifying therapies may be different in the two populations. Understanding the developmental and regulatory pathways for type 1 diabetes-modifying therapies in children will enable industry, academia, funders, advocacy groups, and regulators to translate new science to clinical care. This consensus report characterizes the fundamental differences in type 1 diabetes between children and adults and proposes a thoughtful approach to better understand the development and regulatory pathways for type 1 diabetes therapies.
新出现的数据表明，1型糖尿病在儿童中比在成人中是一种更具侵袭性的疾病，在病理生理学和临床病程方面存在重要差异。因此，改善病情的疗法在这两个人群中的疗效可能不同。了解儿童1型糖尿病改善疗法的发育和调节途径将使产业界、学术界、资助者、倡导团体和监管机构能够将新科学转化为临床护理。本共识报告描述了儿童和成人1型糖尿病的根本差异，并提出了一种深思熟虑的方法，以更好地理解1型糖尿病疗法的开发和监管途径。
Zotero 插件
